# US 2018/0021256 A1 · Process for the preparation of formulations for inhalation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021256 A1
- Document ID: US20180021256A1
- Status: Published application
- Kind: A1
- Application number: 15/324,193
- Filed: 2015-07-08
- Published: 2018-01-25
- Earliest claimed: 2014-07-09
- Applicants: Arven Ilac Sanayi Ve Ticaret A.S.
- Inventors: ALI TÜRKYILMAZ; DEVRIM CELIK; ÖZLEM AKDAS
- Web page: https://patentgrep.com/patent/US20180021256A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/141: {Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K9/16, (co) lyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/50)}
- A61K 9/145: {with organic compounds}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 47/00: Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

## Claims

### Claim 1

The process for the preparation of the dry powder formulation comprising the following steps:
a) the additive is divided into two portions,
b) first portion of the additive is mixed with the pharmaceutically acceptable carrier for a period of time to obtain Premix-1 and second portion of the additive is mixed with the active substance for a period of time to obtain Premix-2,
c) then, Premix-1 and Premix-2 are added into a suitable mixing apparatus and they are mixed for a period of time to obtain the dry powder formulation.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the ratio of the amount of the first portion of the additive to the amount of the second portion of the additive is between 100:1 and 1:100.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the additive is magnesium stearate.

### Claim 4 (depends on 1)

The process according to claim 1, wherein said Premix-1 and Premix-2 is divided into the equal-size portions separately and then, they are added alternately layer by layer in step c) to be mixed.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the pharmaceutically acceptable carrier, the magnesium stearate and the active substance, are added through a suitable screening apparatus.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the pharmaceutically acceptable carrier is selected from the group comprising lactose, mannitol, glucose, trehalose, cellobiose, sorbitol, maltitol or a combination of two or more of them.

### Claim 7 (depends on 6)

The process according to claim 6, wherein the pharmaceutically acceptable carrier is lactose.

### Claim 8 (depends on 6)

The process according to claim 6, wherein the volume median diameter of lactose is between 30 μm and 250 μm.

### Claim 9 (depends on 1)

The process according to claim 1, wherein the amount of the magnesium stearate is less than 1.5% by weight based on the total amount of the dry powder formulation.

### Claim 10 (depends on 9)

The process according to claim 9, wherein the volume median diameter of the magnesium stearate is between 1 μm and 100 μm.

### Claim 11 (depends on 1)

The process according to claim 1, wherein the active substance is in an amount of 0.05% to 2.5% by weight based on the total amount of the dry powder formulation.

### Claim 12 (depends on 1)

The process according to claim 1, wherein the active substance is vilanterol triphenylacetate.
